Homepage | Home | Bookmarke
Member

Byvision Science Technology Limited


Products
  • No Category
Search
 

Friends links
You are here: Home » Products » New Rechargeable Hearing Aids Personal Sound Voice Amplifier In The Ear Mini Audiphone
New Rechargeable Hearing Aids Personal Sound Voice Amplifier In The Ear Mini Audiphone
Click image to view full size image
Product: Views:361New Rechargeable Hearing Aids Personal Sound Voice Amplifier In The Ear Mini Audiphone 
Unit price: Negotiable
MOQ:
Quantity:
Delivery date: Since the payment date Days delivery
Valid until: Long-term effective
Last updated: 2017-09-08 20:48
  Inquiry
Details

new Rechargeable Hearing Aids Personal Sound Voice Amplifier in the ear mini

The new color black of model G-12,is a new rechargeable hearing aid,in the ear mini hearing aid,which can work lasting for 20-30 hours each power charge.It has the Power on/off switcher and the volume adjustable button. This model of mini hearing sound amplifier contains the electronics, controls, microphone and often the loudspeaker.

 

Model No.: G-12

 Product:Rechargeable ITE hearing Aid

 +Unique In the Ear ITE design

 + Adjustable Volume button

 + Power On/Off Switcher

 +package including: User manual, Earplug, USB power adapter,cable and Charge stand

 +Analog,Digital hearing aids,Rechargeable hearing aid,ear hearing amplifier,ITE,CTC models available

 

  FONIX 8000 Test System Data:

Product

MINI Rechargeable ITE hearing amplifier hearing aid      

Technical Data

IEC 60118-7/ANSI S3.22-2003

Model

G-12

Peak OSPL 90 ( dB   SPL)

125dB

HAF OSPL 90 ( dB   SPL)

116dB

Sound Gain

40dB

Total harmonic   wave distortion

≤5%

Frequency range

450Hz-4000Hz

Input Noise

≤30dB

Battery

Li battery rechargeable

Power consumption

DC 3.7V, Current: ≤2mA

Power switcher

Yes, On/Off button

Battery working

Working time 20-30hrs

Package                   

Color box: 4*12*14   cm/unit, Gross weight140g /unit

100 units each carton,Size: 72*40*28CM

Certificates   Approved

CE,FCC & ROHS, and the FDA 2017

Inquiry